Clinical Trial Update: Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating naltrexone/bupropion (Mysimba) for weight outcomes after obesity surgery has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Mysimba (naltrexone/bupropion)

Snippet

Sponsor: Oslo University Hospital | Conditions: Obesity | Phase 4 | Status: WITHDRAWN